Professor of Internal Medicine and Epidemiology
Oncology
Dr. Sofia D. Merajver, MD
|
|
Give Review
Dr. Sofia D. Merajver is an expert in the field of Oncology. He studied medicine at University of Michigan Medical School. He received awards:"CMS Meaningful Use Stage 1 Certification". Sofia Merajver is a published physician as well. He has 94 publications published. The latest was: Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Sofia Merajver accepts Medicare payments and is registered with Medicare.gov.
Publications
- Clinical predictors of long-term survival in HER2-positive metastatic breast Cancer.
- Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
- Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience.
- Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
- Factors related to incomplete treatment of breast Cancer in Kumasi, Ghana.
- Characterizing breast Cancer treatment pathways in Kumasi, Ghana from onset of symptoms to final outcome: Outlook towards Cancer control.
- A Comparison of Criteria to Identify Inflammatory Breast Cancer Cases from Medical Records and the Surveillance, Epidemiology and End Results Data base, 2007-2009.
- Promoters of and barriers to cervical Cancer screening in a rural setting in Tanzania.
- Characterizing inflammatory breast Cancer among Arab Americans in the California, Detroit and New Jersey Surveillance, Epidemiology and End Results (SEER) registries (...
- Assessment of diagnosis of inflammatory breast Cancer cases at two Cancer centers in Egypt and Tunisia.
- Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal Cancer.
- Individual and neighborhood socioeconomic status and healthcare resources in relation to black-white breast Cancer survival disparities.
- Using a state Cancer registry to recruit young breast Cancer survivors and high-risk relatives: protocol of a randomized trial testing the efficacy of a targeted versu...
- Global comparative healthcare effectiveness research: Evaluating sustainable programmes in low & middle resource settings.
- Nanoroughened Surfaces for Efficient Capture of Circulating Tumor Cells without Using Capture Antibodies.
- Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families.
- Inflammatory and non-inflammatory breast Cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.
- Erratum to: Public and Professional Educational Needs for Downstaging Breast Cancer in Egypt.
- Response to comment on "'load-induced modulation of signal transduction networks': reconciling ultrasensitivity with bifunctionality?".
- Unraveling the complex regulatory relationships between metabolism and signal transduction in Cancer.
- Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and moroccan male breast Cancer patients.
- Public and Professional Educational Needs for Downstaging Breast Cancer in Egypt.
- Association of Inflammatory and Non-Inflammatory Breast Cancer with Socioeconomic Characteristics in the Surveillance, Epidemiology, and End Results Database, 2000-2007.
- Making the case for integrated assessments of the biological, social, and system determinants of treatment for breast Cancer to understand and improve outcomes in pati...
- Kinase inhibitors can produce off-target effects and activate linked pathways by retroactivity.
- Differences between women who pursued genetic testing for hereditary breast and ovarian Cancer and their at-risk relatives who did not.
- p38{gamma} promotes breast Cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.
- Survival of Inflammatory Breast Cancer Patients Compared to Non-inflammatory Breast Cancer Patients in Egypt.
- Increased risk for distant metastasis in patients with familial early-stage breast Cancer and high EZH2 expression.
- Androgen receptor polyglutamine tract length in Egyptian male breast Cancer patients.
- Long signaling cascades tend to attenuate retroactivity.
- Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast Cancer.
- Load-induced modulation of signal transduction networks.
- Absence of CHEK2*1100delC mutation in families with hereditary breast Cancer in North America.
- Breast Cancer risk reduction.
- Signaling properties of a covalent modification cycle are altered by a downstream target.
- Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast Cancers.
- One-hit effects and Cancer.
- Multisite phosphorylation provides an effective and flexible mechanism for switch-like protein degradation.
- From in vitro to in silico and back again: using biological and mathematical synergy to decipher breast Cancer cell motility.
- Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary Gland.
- Physiological fluorescence lifetime imaging microscopy improves Förster resonance energy transfer detection in living Cells.
- RhoC expression and head and neck Cancer metastasis.
- Pomegranate fruit extract impairs invasion and motility in human breast Cancer.
- Targeted overexpression of EZH2 in the mammary Gland disrupts ductal morphogenesis and causes epithelial hyperplasia.
- Preclinical development of a bifunctional Cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck Cancer.
- High proportion of inflammatory breast Cancer in the Population-based Cancer Registry of Gharbiah, Egypt.
- A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic Colorectal c...
- On the role of cell signaling models in Cancer research.
- Molecular determinants of the inflammatory breast Cancer phenotype.
- RhoA-GDP regulates RhoB protein stability. Potential involvement of RhoGDIalpha.
- CHEK2 screening: do not think so globally yet.
- Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the Breast epithelium through induction of snail and ZEB1.
- A hidden feedback in signaling cascades is revealed.
- BRCA1 regulates human mammary stem/progenitor Cell fate.
- Genetic determinants of aggressive breast Cancer.
- Picosecond-resolution fluorescence lifetime imaging microscopy: a useful tool for sensing molecular interactions in vivo via FRET.
- CCG-1423: a Small-molecule inhibitor of RhoA transcriptional signaling.
- Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck Cancer.
- Targeted disruption of protein kinase C epsilon reduces Cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous Cell carcinoma.
- RhoC GTPase expression as a potential marker of lymph node metastasis in squamous Cell carcinomas of the head and neck.
- Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast Cancer.
- Identification of EZH2 as a molecular marker for a preCancerous state in morphologically normal breast tissues.
- Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous Cell carcinoma.
- BRCA1 mutation analysis of 41 human breast Cancer cell lines reveals three new deleterious mutants.
- Knowledge gained after a brief CME module on breast Cancer diagnosis.
- Multifaceted role of Rho proteins in angiogenesis.
- Protein kinase C epsilon is a predictive biomarker of aggressive breast Cancer and a validated target for RNA interference antiCancer therapy.
- Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process.
- The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous Cell carcinoma of the head and neck.
- Prognostic factors in oral cavity and oropharyngeal squamous Cell carcinoma.
- WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast Cancer.
- Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma Cells.
- Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade.
- Inhibition of the growth of squamous Cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model.
- Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast Carcinoma.
- Phase II trial of tetrathiomolybdate in patients with advanced kidney Cancer.
- Breast Cancer risk assessment: a guide for clinicians using the NCCN Breast Cancer Risk Reduction Guidelines.
- Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
- Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
- Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate Carcinoma.
- Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the Breast in immunosuppressed hosts.
- Metastatic dedifferentiated Chordoma with elevated beta-hCG: a case report.
- Reversion of RhoC GTPase-induced inflammatory breast Cancer phenotype by treatment with a farnesyl transferase inhibitor.
- Radiotherapy and antiangiogenic TM in lung Cancer.
- Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast Carcinomas with metastatic ability.
- Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population.
- Trends in breast Cancer stage and mortality in michigan (1992-2009) by race, socioeconomic status, and area healthcare resources.
- Trends in Breast Cancer Incidence Rates by Age and Stage at Diagnosis in Gharbiah, Egypt, over 10 Years (1999-2008).
- Cancer classification in the genomic era: five contemporary problems.
- Risk factors for chronic mastitis in morocco and egypt.
- Inferring the Effects of Honokiol on the Notch Signaling Pathway in SW480 Colon Cancer Cells.
- Breast Cancer by Age at Diagnosis in the Gharbiah, Egypt, Population-Based Registry Compared to the United States Surveillance, Epidemiology, and End Results Program, ...
Schools
University of Mi Med Sch
University Of Michigan
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Basal Cell Carcinoma
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Michigan Hospitals and Health Centers -
University of Michigan Medical School
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1568548428 | |
| NPPES Provider LastName | MERAJVER | |
| NPPES Provider FirstName | SOFIA | |
| NPPES Provider ZIPCode | 481095916 | |
| NPPES Provider State | MI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 28.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1568548428 |
| Last Name Of The Provider | MERAJVER |
| First Name Of The Provider | SOFIA |
| View All |
Similar Doctors
|
|
Dr. Rami N. Khoriaty, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Megan E. Caram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dean E. Brenner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Norah L. Henry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sheetal M. Kircher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Qing Li, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Phillip L. Palmbos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Moshe Talpaz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine H. Van Poznak, MD |
|
|
Dr. Scott M. Schuetze, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karim Boudadi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eli L. Gleibermann, MD |
|
|
Dr. Stephen B. Gruber, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|